Seasonality probably means December is not good for OLEMA share price

From past trends, December tends to be when the stock price takes a dive as investors are looking at other more dynamic stocks to invest in. Feb and Jul seems to be when the stock price tends to get an uplift. The drop off is especially drastic this Dec given the significant interest in all things crypto, Trump and AI related after the recent election.

There's been generally good news from Olema of late, especially the very positive Opera 2 phase 1b/2 read out after 6 months of trials shared at SABC. That Bain owns 9.9% as of Dec 4 is also significant - it's a mark of confidence in the potential of Palazestrant. Phase 3 trial results in 2025 with a large patient sample, made possible with the securement of USD250M in capital, will be most exciting given the results seen in 1b/2. Hence there is generally nothing negative about Olema's progress that is influencing the current stock price.

Once again, there's every chance that Novartis may eventually buy over Olema to secure Ribociclib which is now becoming the defacto breast cancer drug of choice.